Emerging Therapies
There are numerous new treatments in late-stage development
in the MS research pipeline. Those agents
that have completed or are in phase 3 trials include
laquinimod, alemtuzumab, and daclizumab. Laquinimod
is an oral treatment, alemtuzumab is administered intravenously
once yearly over several days, and daclizumab
is administered subcutaneously every 2 or 4 weeks.
Alemtuzumab is currently under FDA review for potential
approval as a DMT for MS.